- A total market capitalization of €13.9Bn, a valuation close to the historical highs observed for the sector.
- Valuation levels up sharply, with a general improvement in market trends in the sector.
- Interest in the sector confirmed to investors (observed in the last quarter of 2016), with rising levels of liquidity and capital invested:
> Trading volumes on average per day up +41%
> A stable number of investors in the capital of the 47 listed biotechs (335 institutional)
> A positive estimate of the investment flows to companies over 3 months, with approximately €113M net of capital invested in the companies of the panel.
> Total amounts raised between January and April (€572.1M) increased by +164% compared to the same period in 2016 (€216.7M), with three times more funds raised via secondary issuance of shares And +21% via IPOs.